| HOME >> MEDICINE >> TECHNOLOGY |
Albuferon 1200-mcg Every Two Weeks (Albuferon 1200 Q2w)
-- ITT analysis shows that 55.5% of patients in the Albuferon 1200 Q2w
treatment group achieved SVR, vs. 57.9% for peginterferon alfa-2a
administered every week.
-- In heavier patients (75 kg or heavier) who were treatment-adherent,
67.9% of those in the Albuferon 1200 Q2w treatment group achieved SVR,
versus 53.3% for peginterferon alfa-2a every week.
-- Among all treatment-adherent patients in the Albuferon 1200 Q2w
treatment group, 70.6% achieved SVR, versus 66.7% for peginterferon
alfa-2a.
-- ITT analysis shows that the Albuferon 1200 Q2w treatment group
exhibited a robust early antiviral response (reduction in hepatitis C
RNA viral load to below the level of quantitation): 74.5% for
Albuferon 1200 Q2w at Week 12, vs. 65.8% for peginterferon alfa-2a.
The Albuferon 1200 Q2w treatment group also had the most rapid time to
HCV RNA negativity.
-- The rate of discontinuations due to adverse events was 18.2% in the
Albuferon 1200 Q2w treatment group, vs. 6.1% in the peginterferon alfa-
2a group. Adverse events observed were those typically expected with
interferon therapy. Dose reductions were attempted in only 24.4% of
Albuferon subjects prior to discontinuation, versus 42.9% for
peginterferon alfa-2a. Adverse events observed were those typically
expected with interferon therapy.
"In the Albuferon Phase 3 trials, we are strongly encouraging titration of dose where necessary to increase tolerability, reduce the rate of discontinuations, and maximize the therapeutic benefit of the robust early antiviral response offered by the 1200-microgram dose on a two-week administration schedule," said Dr. Stump.
Albuferon 1200-mcg Monthly (Albuferon 1200 Q4w)
-- ITT analysis shows that 50.9% of patients in the Albuferon
'/>"/>
| SOURCE Human Genome Sciences, Inc. Copyright©2007 PR Newswire. All rights reserved |